- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Hypha Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mo | Hypha Labs, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 31.12.24 | Hypha Labs, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| HYPHA LABS Aktie jetzt für 0€ handeln | |||||
| 16.12.24 | Hypha Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.11.24 | Hypha Labs, Inc.: Hypha Laboratories Announces Completion of Phase 1 of Its State-of-the-Art Facility and Arrival of V5 Working MicroPearls Prototypes | 228 | ACCESS Newswire | Advancements Enhance Efficacy in Hypha's Revolutionary Home and Commercial Production UnitsLAS VEGAS, NV / ACCESSWIRE / November 18, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
| 17.10.24 | Hypha Labs Inc. and Emerging Markets Consulting LLC: Emerging Markets Report: A Mushroom Monster in the Making | 1 | GlobeNewswire (USA) | ||
| 15.10.24 | Hypha Labs, Inc.: Hypha Laboratories Establishes Scientific and Cultural Advisory Board, Adds William Padilla-Brown | 234 | ACCESS Newswire | Board Will Add to Company's Intellectual Capital and Diversity of ExperienceLAS VEGAS, NV / ACCESSWIRE / October 15, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and... ► Artikel lesen | |
| 07.10.24 | Hypha Labs, Inc.: Hypha Laboratories Reveals New Patent Applications for Novel A.I. Driven In-Home Mycelium Production | 255 | ACCESS Newswire | Company Intends to Bring First Functional Mushroom Producer to RetailLAS VEGAS, NV / ACCESSWIRE / October 7, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator... ► Artikel lesen | |
| 30.09.24 | Hypha Labs, Inc. Reveals First Functional Mushroom Ingredient Array for Home and Commercial Production | 219 | ACCESS Newswire | First Generation 'MicroPearls Pro'and "MicroPearls ProX" Will Support Largest Mushroom Ingredient CategoriesLAS VEGAS, NV / ACCESSWIRE / September 30, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer... ► Artikel lesen | |
| 26.09.24 | Hypha Labs, Inc.: Functional Mushroom Company Hypha Labs Retains Emerging Markets Consulting LLC for Investor Relations Advisory Services | 229 | ACCESS Newswire | LAS VEGAS, NV / ACCESSWIRE / September 26, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences, is pleased to announce that the Company has retained Emerging Markets Consulting... ► Artikel lesen | |
| 23.09.24 | Hypha Labs, Inc. Releases Investor Presentation | 247 | ACCESS Newswire | Dynamic Deck Outlines Company's Plan to Empower Home and Commercial Production of Functional Mushroom Ingredients LAS VEGAS, NV / ACCESSWIRE / September 23, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer... ► Artikel lesen | |
| 16.09.24 | Hypha Labs, Inc. Uplists to the OTCQB | 320 | ACCESS Newswire | OTCQB Listing Brings Transparency, Prestige and Beneficial Exposure LAS VEGAS, NV / ACCESSWIRE / September 16, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences, is pleased... ► Artikel lesen | |
| 20.08.24 | Hypha Labs, Inc.: Hypha Labs' Revolutionary Psilocybin Bioreactor Nominated for Best New Product of 2024 by Santa Monica Daily Press | 277 | ACCESS Newswire | LAS VEGAS, NV / ACCESSWIRE / August 20, 2024 / Hypha Labs, Inc. (OTC PINK:FUNI), a pioneer in functional mushroom sciences, is pleased to announce that the Company's proprietary bioreactor which allows... ► Artikel lesen | |
| 14.08.24 | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08.24 | Digipath Name and Symbol Change Approved, Company Begins Trading as Hypha Labs, Inc. | 523 | ACCESS Newswire | LAS VEGAS, NV / ACCESSWIRE / August 13, 2024 / Hypha Labs, Inc. formerly (OTC PINK:DIGP), has been approved to commence trading as Hypha Labs, Inc. (OTC PINK:FUNI) on August 13, 2024. Hypha Labs has... ► Artikel lesen | |
| 31.07.24 | Hypha Labs, Inc.: Hypha Labs' Revolutionary Psilocybin Bioreactor Nominated for Best New Product of 2024 by Santa Monica Daily Press | 352 | ACCESS Newswire | LAS VEGAS, NV / ACCESSWIRE / July 31, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP), a pioneer in functional mushroom sciences, is pleased to announce that the Company's proprietary bioreactor which allows... ► Artikel lesen | |
| 20.07.24 | Hypha Labs, Inc.: Hypha Laboratories Retains Integrity Media for Investor Relations and Corporate Communications | 1.177 | ACCESS Newswire | Veteran Agency Brings Twenty-Five Years of Experience and Relationships to Emerging Functional Mushroom Science CompanyLAS VEGAS, NV / ACCESSWIRE / July 19, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP),... ► Artikel lesen | |
| 20.07.24 | Hypha Labs, Inc.: Hypha Laboratories Reveals New Patent Applications for Novel Artificial Intelligence Driven In-Home Mycelium Production | 1.213 | ACCESS Newswire | Company Intends to Bring First Functional Mushroom Producer to RetailLAS VEGAS, NV / ACCESSWIRE / July 19, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP), a pioneer in functional mushroom sciences, is pleased... ► Artikel lesen | |
| 20.05.24 | Hypha Labs, Inc.: Hypha Labs Announces New Patent Filing | 505 | ACCESS Newswire | New Patent Portfolio Unveiled Revolutionizing Psilocybin ProcessingLAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP) Today marks a significant milestone in the realm of mycological... ► Artikel lesen | |
| 29.04.24 | Hypha Labs, Inc.: Hypha Labs Names Craig Ellins Chief Science Officer | 517 | ACCESS Newswire | LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Hypha Labs, Inc. (OTC Pink:DIGP) has announced that it has made Craig Ellins its Chief Science Officer. Hypha Labs, Inc. changed its name from Digipath... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,935 | +0,65 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Aktienrückkauf
QIAGEN N.V.: QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück... ► Artikel lesen | |
| KEROS THERAPEUTICS | 10,860 | +3,04 % | Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) | ||
| BIONTECH | 109,20 | +0,18 % | BioNTech Aktie testet Widerstände: Kommt der nächste Ausbruch? | Die BioNTech Aktie befindet sich in einer spannenden charttechnischen Phase mit einem NASDAQ-Schlusskurs vom Freitag bei 122,85 US-Dollar und einer insgesamt positiven Entwicklung seit Mitte des Jahres.... ► Artikel lesen | |
| EVOTEC | 7,990 | +3,30 % | Aixtron, BMW, Evotec, Gerresheimer, Lufthansa, TUI u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| NURIX THERAPEUTICS | 19,140 | -1,80 % | Nurix Therapeutics, Inc. - 8-K, Current Report | ||
| TEMPUS AI | 35,150 | +1,15 % | Tempus AI (NASDAQ:TEM) Shares Up 11.7% - Should You Buy? | ||
| SUMMIT THERAPEUTICS | 19,020 | +4,56 % | Looking At Summit Therapeutics' Recent Unusual Options Activity | ||
| ADMA BIOLOGICS | 16,000 | -3,79 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 12,540 | +1,13 % | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 34,590 | -2,81 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 28,905 | +2,35 % | Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential | ||
| RECURSION PHARMACEUTICALS | 6,525 | +1,95 % | Is Recursion Pharmaceuticals Stock a Buy? | ||
| SANA BIOTECHNOLOGY | 3,160 | -2,77 % | Sana Biotechnology, Inc. - 8-K, Current Report | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 43,900 | +5,86 % | MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset | ||
| DYNE THERAPEUTICS | 14,120 | -4,30 % | Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1 | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).... ► Artikel lesen |
Das Unternehmen HYPHA LABS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HYPHA LABS INC finden Sie auf Wallstreet Online.
